 NEW YORK, Oct. 19, 2021 PRNewswire -- Petros Pharmaceuticals, Inc. Nasdaq: PTPI, a leading provider of therapeutics for mens health, today announced the closing of its previously announced registered direct offering with the companys largest and other existing investors for gross proceeds of approximately 5.7 million. Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its mens health platform and for working capital and general corporate purposes. 